Neoleukin Therapeutics Inc reports results for the quarter ended in March - Earnings Summary

Neurogene

10/05/2022 22:01

* Neoleukin Therapeutics Inc  NLTX.OQ  reported a quarterly
adjusted loss of 28 cents​​ per share for the quarter ended in
March. The mean expectation of six analysts for the quarter was
for a loss of 30 cents per share.
    * Reported revenue was zero​;  analysts expected zero. 
    * Neoleukin Therapeutics Inc's reported EPS for the quarter
was a
loss of 28 cents​.
    * The mean earnings estimate of analysts had risen by
about 6.7%
in the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Neoleukin Therapeutics Inc shares had fallen by 39.4% this
quarter and lost 76.3% so far this year.
    * The company reported a quarterly loss of $15.35 million.
    * Wall Street's median 12-month price target for Neoleukin
Therapeutics Inc is $20.00 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 7 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 

This summary was machine generated May 10 at 09:00 p.m.  ​All
figures in US dollars unless otherwise stated